JP2022545167A5 - - Google Patents
Info
- Publication number
- JP2022545167A5 JP2022545167A5 JP2022505440A JP2022505440A JP2022545167A5 JP 2022545167 A5 JP2022545167 A5 JP 2022545167A5 JP 2022505440 A JP2022505440 A JP 2022505440A JP 2022505440 A JP2022505440 A JP 2022505440A JP 2022545167 A5 JP2022545167 A5 JP 2022545167A5
- Authority
- JP
- Japan
- Prior art keywords
- tgf
- receptor
- chimeric cytokine
- cytokine receptor
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962894658P | 2019-08-30 | 2019-08-30 | |
| US62/894,658 | 2019-08-30 | ||
| US202063053322P | 2020-07-17 | 2020-07-17 | |
| US63/053,322 | 2020-07-17 | ||
| PCT/US2020/048402 WO2021041806A1 (en) | 2019-08-30 | 2020-08-28 | Chimeric cytokine receptors comprising tgf beta binding domains |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022545167A JP2022545167A (ja) | 2022-10-26 |
| JP2022545167A5 true JP2022545167A5 (cg-RX-API-DMAC7.html) | 2023-09-01 |
Family
ID=72521701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022505440A Pending JP2022545167A (ja) | 2019-08-30 | 2020-08-28 | Tgfベータ結合ドメインを含むキメラサイトカイン受容体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12528856B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4021582A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022545167A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220052919A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114341193A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020336131B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022003553A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3145614A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL290960A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022002297A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021041806A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL285941B1 (en) * | 2019-03-01 | 2026-08-01 | Allogene Therapeutics Inc | Cytokine chemoreceptors bearing the PD-1 ECTODOMAIN |
| WO2022020456A2 (en) | 2020-07-21 | 2022-01-27 | Allogene Therapeutics, Inc. | Chimeric antigen receptors with enhanced signaling and activities and uses thereof |
| CN117120075A (zh) * | 2021-02-17 | 2023-11-24 | 库拉治疗股份有限公司 | 抗病原体白细胞介素-TGF-β受体融合多肽 |
| CA3217252A1 (en) * | 2021-04-19 | 2022-10-27 | Nanjing Legend Biotech Co., Ltd. | Chimeric cytokine receptors and uses thereof in cellular therapies |
| CA3230292A1 (en) | 2021-08-27 | 2023-03-02 | Theranotics Co., Ltd. | Bispecific molecule specifically binding to b7-h3 and tgfb and uses thereof |
| CN115873802A (zh) * | 2021-09-29 | 2023-03-31 | 亘喜生物科技(上海)有限公司 | 嵌合抗原受体免疫细胞及其制法和应用 |
| US20250041336A1 (en) * | 2021-09-29 | 2025-02-06 | Vita Therapeutics, Inc. | Methods and compositions for treating cancer with engineered cells |
| JP2024539013A (ja) * | 2021-10-20 | 2024-10-28 | フェイト セラピューティクス,インコーポレイティド | 固形腫瘍における同種異系養子細胞療法のためのエフェクター細胞及びその使用 |
| GB202117298D0 (en) * | 2021-11-30 | 2022-01-12 | Quell Therapeutics Ltd | Signalling protein |
| EP4479068A4 (en) * | 2022-02-18 | 2026-01-07 | Univ California | ENHANCED MULTIPLICATION AND FUNCTION OF PRIMARY HUMAN NK CELLS BY A CHIMERICAL CYTOKINE RECEPTOR |
| EP4499680A1 (en) * | 2022-03-29 | 2025-02-05 | Allogene Therapeutics, Inc. | Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals |
| GB202301421D0 (en) * | 2023-02-01 | 2023-03-15 | Univ Oslo Hf | Switch receptor for use in adoptive cell therapy |
| CN116284449B (zh) * | 2023-02-27 | 2024-11-19 | 深圳市先康达生命科学有限公司 | 增强型TGF-βR嵌合受体及其应用 |
| EP4724086A1 (en) * | 2023-06-06 | 2026-04-15 | F. Hoffmann-La Roche AG | Switch receptors |
| CN121532650A (zh) | 2023-06-20 | 2026-02-13 | 艾洛基治疗公司 | 工程化的细胞的检测方法 |
| KR20260105764A (ko) | 2023-10-30 | 2026-07-07 | 알로젠 테라퓨틱스 인코포레이티드 | 조작된 세포 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL114825A0 (en) | 1994-08-04 | 1995-12-08 | Regeneron Pharma | Rtk/cytokine receptor chimeras |
| US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
| WO1998002558A2 (en) | 1996-07-17 | 1998-01-22 | University Of Medicine And Dentistry Of New Jersey | Chimeric receptors for jak-stat signal transduction |
| EP1033374B1 (en) | 1997-11-26 | 2012-08-01 | Chugai Seiyaku Kabushiki Kaisha | Signal sequence trapping method |
| WO2007075899A2 (en) | 2005-12-21 | 2007-07-05 | Maxygen, Inc. | Dual agonist compounds and uses thereof |
| US8389282B2 (en) | 2007-03-30 | 2013-03-05 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| AU2009292996B2 (en) | 2008-09-22 | 2015-04-23 | Baylor College Of Medicine | Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters |
| WO2011069004A1 (en) | 2009-12-04 | 2011-06-09 | Quest Diagnostics Investments Incorporated | Mpl mutations in jak2 v617f negative patients with myeloproliferative disease |
| EP2694640B1 (en) | 2011-04-08 | 2017-10-18 | Baylor College Of Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| MX2014001222A (es) | 2011-07-29 | 2014-09-15 | Univ Pennsylvania | Receptores coestimuladores de cambio. |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| US9434935B2 (en) | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
| CA2905352A1 (en) | 2013-03-14 | 2014-09-25 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
| WO2014172584A1 (en) * | 2013-04-17 | 2014-10-23 | Baylor College Of Medicine | IMMUNOSUPPRESSIVE TGF-β SIGNAL CONVERTER |
| EP3569253A1 (en) | 2013-06-05 | 2019-11-20 | Bellicum Pharmaceuticals, Inc. | Methods for inducing partial apoptosis using caspase polypeptides |
| WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
| AU2015330017A1 (en) | 2014-10-07 | 2017-04-27 | Cellectis | Method for modulating car-induced immune cells activity |
| MA41538A (fr) * | 2014-10-17 | 2017-12-26 | Baylor College Medicine | Cellules immunitaires bipartites et tripartites de signalisation |
| DK3227339T3 (da) | 2014-12-05 | 2022-01-10 | Memorial Sloan Kettering Cancer Center | Kimæriske antigenreceptorer rettet mod g-protein-koblet receptor og anvendelser deraf |
| EP3234145B1 (en) | 2014-12-15 | 2019-06-05 | Bellicum Pharmaceuticals, Inc. | Methods for controlled activation or elimination of therapeutic cells |
| EP3250602A1 (en) | 2015-01-26 | 2017-12-06 | Cellectis | T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm |
| CA2974998C (en) | 2015-02-12 | 2022-04-26 | Takara Bio Inc. | Chimeric antigen receptors |
| HUE057285T2 (hu) | 2015-04-13 | 2022-04-28 | Pfizer | Terápiás ellenanyagok és alkalmazásaik |
| TWI700298B (zh) | 2015-04-13 | 2020-08-01 | 美商輝瑞股份有限公司 | 靶向b細胞成熟抗原之嵌合型抗原受體類 |
| WO2016168612A1 (en) | 2015-04-15 | 2016-10-20 | Promedior, Inc. | Methods for treating myeloproliferative disorders |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| GB201518816D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| EP3368571B1 (en) * | 2015-10-30 | 2022-12-07 | The Regents of The University of California | Transforming growth factor-beta-responsive polypeptides and their methods for use |
| GB201522097D0 (en) * | 2015-12-15 | 2016-01-27 | Cellular Therapeutics Ltd | Cells |
| WO2018161064A1 (en) | 2017-03-03 | 2018-09-07 | F1 Oncology, Inc. | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof |
| WO2019055946A1 (en) * | 2017-09-18 | 2019-03-21 | F1 Oncology, Inc. | METHODS AND COMPOSITIONS FOR THE GENETIC MODIFICATION AND EXPANSION OF LYMPHOCYTES AND THE REGULATION OF THE ACTIVITY THEREOF |
| CN106399255B (zh) | 2016-04-13 | 2019-10-18 | 阿思科力(苏州)生物科技有限公司 | Pd-1 car-t细胞及其制备方法和应用 |
| CN118546961A (zh) * | 2016-08-26 | 2024-08-27 | 贝勒医学院 | 用于细胞治疗的组成型活性细胞因子受体 |
| US11654158B2 (en) * | 2016-11-17 | 2023-05-23 | 2Seventy Bio, Inc. | TGFBeta signal convertor |
| WO2018104473A1 (en) | 2016-12-07 | 2018-06-14 | Oslo Universitetssykehus Hf | Compositions and methods for cell therapy |
| GB201702617D0 (en) | 2017-02-17 | 2017-04-05 | Autolus Ltd | Receptor |
| JP7282760B2 (ja) | 2017-10-18 | 2023-05-29 | アルパイン イミューン サイエンシズ インコーポレイテッド | バリアントicosリガンド免疫調節タンパク質ならびに関連する組成物および方法 |
| GB201719557D0 (en) | 2017-11-24 | 2018-01-10 | Autolus Ltd | Polypeptide |
| US11738047B2 (en) | 2017-12-12 | 2023-08-29 | The Trustees Of The University Of Pennsylvania | Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof |
| AU2019227979B2 (en) | 2018-03-02 | 2024-09-05 | Allogene Therapeutics, Inc. | Inducible chimeric cytokine receptors |
| CN112533942A (zh) | 2018-06-01 | 2021-03-19 | 华盛顿大学 | 嵌合抗原受体细胞疗法中细胞因子释放综合征的抑制 |
| CN112368298A (zh) | 2018-06-22 | 2021-02-12 | 凯德药业股份有限公司 | 嵌合跨膜蛋白及其用途 |
| GB201814203D0 (en) | 2018-08-31 | 2018-10-17 | King S College London | Engineered regulatory t cell |
| IL328846A (en) | 2019-03-01 | 2026-08-01 | Allogene Therapeutics Inc | Constitutively active chimeric cytokine receptors and compounds comprising them for the treatment of cancer and autoimmune diseases |
| IL285941B1 (en) * | 2019-03-01 | 2026-08-01 | Allogene Therapeutics Inc | Cytokine chemoreceptors bearing the PD-1 ECTODOMAIN |
-
2020
- 2020-08-28 BR BR112022003553A patent/BR112022003553A2/pt unknown
- 2020-08-28 US US17/005,757 patent/US12528856B2/en active Active
- 2020-08-28 CA CA3145614A patent/CA3145614A1/en active Pending
- 2020-08-28 JP JP2022505440A patent/JP2022545167A/ja active Pending
- 2020-08-28 EP EP20772464.2A patent/EP4021582A1/en active Pending
- 2020-08-28 KR KR1020227004538A patent/KR20220052919A/ko active Pending
- 2020-08-28 WO PCT/US2020/048402 patent/WO2021041806A1/en not_active Ceased
- 2020-08-28 MX MX2022002297A patent/MX2022002297A/es unknown
- 2020-08-28 AU AU2020336131A patent/AU2020336131B2/en active Active
- 2020-08-28 CN CN202080061119.3A patent/CN114341193A/zh active Pending
-
2022
- 2022-02-27 IL IL290960A patent/IL290960A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7179041B2 (ja) | 三官能性t細胞-抗原カプラ及び方法並びにこれらの使用 | |
| AU2020336131B2 (en) | Chimeric cytokine receptors comprising TGF beta binding domains | |
| IL273201B1 (en) | Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy | |
| CN110616191B (zh) | 共刺激配体联合的car t疗法 | |
| JP2022537824A5 (cg-RX-API-DMAC7.html) | ||
| JP2023552998A5 (cg-RX-API-DMAC7.html) | ||
| CN110511912B (zh) | 免疫细胞的功能调节 | |
| JP7227630B2 (ja) | Y182t突然変異を有するt細胞-抗原カプラおよびその方法ならびに使用 | |
| JP2017504601A5 (cg-RX-API-DMAC7.html) | ||
| JP2022512913A5 (cg-RX-API-DMAC7.html) | ||
| JP7404279B2 (ja) | 様々な構築物最適化を備えたt細胞抗原カプラ | |
| JP2024510900A5 (cg-RX-API-DMAC7.html) | ||
| US20210379149A1 (en) | Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy | |
| CN108138148A (zh) | T细胞的激活和扩增 | |
| CN111019905A (zh) | Car修饰细胞及其在制备自身免疫性疾病药物中的应用 | |
| JP2023548974A (ja) | T細胞抗原カプラを含む細胞及びその使用 | |
| JP2022525925A5 (cg-RX-API-DMAC7.html) | ||
| CN111826353A (zh) | 调节t细胞功能和反应的方法 | |
| CN115873801A (zh) | 工程化免疫细胞及其用途 | |
| CN119661725A (zh) | Il5ra细胞表面标记物 | |
| JP2025506515A5 (cg-RX-API-DMAC7.html) | ||
| CN112251452A (zh) | Til/tcr-t细胞治疗平台 | |
| WO2024011335A1 (zh) | 经修饰的免疫细胞 | |
| HK40054580A (en) | Trifunctional t cell-antigen coupler and methods and uses thereof | |
| CN119998452A (zh) | 编码car的核酸分子和包含其的载体、car、包含car的免疫细胞和包含该细胞的药物组合物及包含car的免疫细胞的制备方法 |